Table 1. Characteristics of a Cohort of 15 637 Transgender Adults and a Cohort of 46 911 Cisgender Adults in the US, 2017.
Characteristic | No. (%) | Bivariate comparisonsa | ||
---|---|---|---|---|
Transgender (n = 15 637) | Cisgender (n = 46 911) | χ2 | P value | |
Geographic regionb | ||||
Northeast | 1963 (12.6) | 5889 (12.6) | NA | NA |
Midwest | 3760 (24.0) | 11 280 (24.0) | ||
West | 3432 (21.9) | 10 296 (21.9) | ||
South | 6482 (41.5) | 19 446 (41.5) | ||
Age, y | ||||
18-25 | 4084 (26.1) | 12 252 (26.1) | NA | NA |
26-30 | 1858 (11.9) | 5574 (11.9) | ||
31-35 | 1369 (8.8) | 4107 (8.8) | ||
36-40 | 1316 (8.4) | 3948 (8.4) | ||
41-45 | 1167 (7.5) | 3501 (7.5) | ||
45-50 | 1302 (8.3) | 3906 (8.3) | ||
51-55 | 1257 (8.0) | 3771 (8.0) | ||
56-60 | 1154 (7.4) | 3462 (7.4) | ||
≥61 | 2130 (13.6) | 6390 (13.6) | ||
Gender spectrum | ||||
Transfeminine | 2079 (13.3) | NA | NA | NA |
Transmasculine | 4955 (31.7) | NA | ||
Unknown gender | 8603 (55.0) | NA | ||
Male | NA | 23 664 (50.4) | ||
Female | NA | 23 247 (49.6) | ||
SUDDs | ||||
Polysubstance | 310 (2.0) | 245 (0.5) | 284.3 | <.001 |
Nicotine | 2594 (16.6) | 2551 (5.4) | 1931.7 | <.001 |
Alcohol and drug | 887 (5.7) | 820 (1.7) | 680.4 | <.001 |
Alcohol | 401 (2.6) | 438 (0.9) | 235.7 | <.001 |
Drug | 678 (4.3) | 549 (1.2) | 611.1 | <.001 |
Cannabis | 321 (2.1) | 186 (0.4) | 400.2 | <.001 |
Cocaine | 81 (0.5) | 59 (0.1) | 80.8 | <.001 |
Opioid | 205 (1.3) | 207 (0.4) | 135.6 | <.001 |
Another drugc | 265 (1.7) | 183 (0.4) | 280.7 | <.001 |
Abbreviations: NA, not applicable; SUDD, substance use disorder diagnoses.
Bivariate comparisons are not reported for age and geographic region because the cisgender cohort was matched 3 to 1 to the transgender cohort based on these characteristics.
Hawaii and Alaska are included in the West according to the US Census. US territories (eg, Puerto Rico and Guam) are not included in US Census regions; thus the approximately 100 individuals without an assigned census region were included in the South.
Another drug SUDD includes hallucinogens, sedatives, stimulants, and the diagnosis of other SUD not otherwise specified.